Viridian Therapeutics, Inc.
VRDN
$13.13
$0.483.79%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -16.28% | 19.44% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -16.28% | 19.44% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -277,055.81% | 101.50% | |||
| SG&A Expenses | 8.16% | -10.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 4.76% | 15.65% | |||
| Operating Income | -4.78% | -15.64% | |||
| Income Before Tax | -3.96% | -18.00% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -3.96% | -18.00% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -3.96% | -18.00% | |||
| EBIT | -4.78% | -15.64% | |||
| EBITDA | -4.80% | -15.69% | |||
| EPS Basic | 80.16% | -13.44% | |||
| Normalized Basic EPS | 13.19% | -13.08% | |||
| EPS Diluted | 80.16% | -13.44% | |||
| Normalized Diluted EPS | 13.19% | -13.08% | |||
| Average Basic Shares Outstanding | 20.52% | 4.02% | |||
| Average Diluted Shares Outstanding | 20.52% | 4.02% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||